Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Adam Crisp"'
Autor:
Dimitra Skoumpopoulou, Adam Crisp
Publikováno v:
Engineering Science & Technology. :113-120
Technology is a rapidly developing concept and its development is second to none while technology and the Internet is more available than ever. Its uses range from personal use, up to and including large corporate organisations. However, this study w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2014fb436a2b6f2c462832965d23e64c
https://doi.org/10.37256/est.212021382
https://doi.org/10.37256/est.212021382
Autor:
Stefan D. Anker, Milton Packer, J. Wouter Jukema, Mark A. Hlatky, Adam Crisp, Hossein Ardeschir Ghofrani, Ransi Somaratne, Martin R. Cowie, Richard Holcomb, Béla Merkely, Narimon Honarpour, Giuseppe M.C. Rosano, Savion Gropper, Dan Atar, Gerhard Hindricks, Ulf Landmesser, Albert M. Kim, Wendy Gattis Stough, Fabienne Dominjon, Theresa McDonagh, James H. Revkin, John J.V. McMurray, Martin Lefkowitz, Stefan Schroeder, Adriaan A. Voors, Krishna Prasad, Ian Ford, Chantal Le Floch, Claudio Ceconi, Frank Ruschitzka, Michael Kunz, Jeroen J. Bax
Publikováno v:
European Journal of Heart Failure. 18:482-489
Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of patients to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38b4c4f51f5ecae13e61db7a7ed8cce7
https://doi.org/10.1002/ejhf.516
https://doi.org/10.1002/ejhf.516
Autor:
Adam Crisp
Publikováno v:
Contemporary Clinical Trials. 43:155-163
Blinding is a corner-stone for the robustness of many clinical trials. Achieving a robust level of trial blinding involves close partnership across a number of trial disciplines, and numerous challenges can arise. This paper provides a wide-ranging o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0d6d043f937a3ef0c7e3c4afa7ab564
https://doi.org/10.1016/j.cct.2015.06.002
https://doi.org/10.1016/j.cct.2015.06.002
Publikováno v:
Pharmaceutical statistics. 17(4)
All clinical trials are designed for success of their primary objectives. Hence, evaluating the probability of success (PoS) should be a key focus at the design stage both to support funding approval from sponsor governance boards and to inform trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61feafe47fd51645aeb9e5bacf63323d
https://pubmed.ncbi.nlm.nih.gov/29635777
https://pubmed.ncbi.nlm.nih.gov/29635777
Autor:
John J.V. McMurray, James H. Revkin, Ulf Landmesser, Dan Atar, Ransi Somaratne, Richard Holcomb, Narimon Honarpour, Stefan D. Anker, Stefan Schroeder, Jeroen J. Bax, Giuseppe M.C. Rosano, Gerhard Hindricks, Martin R. Cowie, Michael Kunz, Savion Gropper, Frank Ruschitzka, Martin Lefkowitz, Adriaan A. Voors, Theresa McDonagh, Fabienne Dominjon, J. Wouter Jukema, Milton Packer, Béla Merkely, Mark A. Hlatky, Hossein Ardeschir Ghofrani, Claudio Ceconi, Ian Ford, Chantal Le Floch, Krishna Prasad, Adam Crisp, Wendy Gattis Stough, Albert M. Kim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2e91bc180ccfddb436f55f9994a212d
http://hdl.handle.net/10044/1/43465
http://hdl.handle.net/10044/1/43465
Autor:
Bruno Mihout, Hartmut Göbel, Werner Becher, Jesper Tørring, Paul Winter, Jur Niewold, Adam Crisp, Tove Hange, Diane Boswell
Publikováno v:
Clinical Therapeutics. 22:981-989
Objective This randomized, double-blind, crossover study was undertaken to compare the incidence of headache recurrence after treatment with naratriptan or sumatriptan in migraine patients with a history of frequent headache recurrence (recurrence in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3ed8d9349a43e2e16c783eb0ad667b3
https://doi.org/10.1016/s0149-2918(00)80069-7
https://doi.org/10.1016/s0149-2918(00)80069-7
Autor:
Douglas Norman, Michael R. Keating, Ira C. Lee, Adam Crisp, Patrick J. Brennan, Hans H. Neumayer, Gary L. Coggon, Christophe Legendre, Jean-Paul Squifflet, Josef Kovarik, David C. Lowance, Rafael Mendez
Publikováno v:
New England Journal of Medicine. 340:1462-1470
Background Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease. Methods A total of 208 CMV-negative recipients of a kidney
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6579eff62cf56f7a45271fe0e03695c
https://doi.org/10.1056/nejm199905133401903
https://doi.org/10.1056/nejm199905133401903
Autor:
Dimitri Tousoulis, Adam Crisp, Nigel Legg, Duncan J Anderson, Paul D O B Winter, Roberto Lorenzoni, Tomaso Gnecchi-Ruscone, Paolo G. Camici
Publikováno v:
The American Journal of Cardiology. 81:1165-1168
The effects of intravenous ergotamine (0.25 mg) on basal and hyperemic (dipyridamole) myocardial blood flow (MBF), measured with positron emission tomography and H2(15)O, were assessed in 15 migraineurs in a double-blind, randomized, placebo controll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26d049fd0543f48abc30ce41d83515ed
https://doi.org/10.1016/s0002-9149(98)00029-0
https://doi.org/10.1016/s0002-9149(98)00029-0
Autor:
Paula S. Curtis, Adam Crisp
Publikováno v:
Pharmaceutical statistics. 7(4)
We consider the problem of sample size calculation for non-inferiority based on the hazard ratio in time-to-event trials where overall study duration is fixed and subject enrollment is staggered with variable follow-up. An adaptation of previously de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e0ff1baf433d9d1aae5353bac1edb51
https://pubmed.ncbi.nlm.nih.gov/17583558
https://pubmed.ncbi.nlm.nih.gov/17583558
Autor:
David A. Morrow, P. Gabriel Steg, Philip E. Aylward, Pierre Théroux, Michelle L. O'Donoghue, Jose Lopez-Sendon, Matthew A. Cavender, Marc S. Sabatine, Ian Laws, Keith A.A. Fox, Ruchira Glaser, Adam Crisp
Publikováno v:
American Heart Journal. 169:622-630.e6
Background p38 mitogen-activated protein kinase (MAPK) mediates cytokine production and amplification of the inflammatory cascade. Through inhibition of p38 MAPK, losmapimod appears to attenuate the inflammatory response in the vascular wall and thus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b46580283d69c45aa3a51744f307cf2
https://doi.org/10.1016/j.ahj.2015.02.012
https://doi.org/10.1016/j.ahj.2015.02.012